相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia
Fary Diop et al.
HAEMATOLOGICA (2020)
Risk of Infection Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Somedeb Ball et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma
Cho-Hao Lin et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties
Saul Jaime-Figueroa et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure
Jordan Gauthier et al.
BLOOD (2020)
Genomic evolution of ibrutinib-resistant clones in Waldenstrom macroglobulinaemia
Cristina Jimenez et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Interleukin-1 receptor-associated kinase 4 inhibitor interrupts toll-like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis
Vincenza Simona Delvecchio et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib-resistant non-nodal leukemic mantle cell lymphoma
Xiang Zhou et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2020)
Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma
Yun Chen et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Impact and Intricacies of Bone Marrow Microenvironment in B-cell Lymphomas: From Biology to Therapy
Anuvrat Sircar et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia
Ola A. Elgamal et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib
Jim S. Qin et al.
JOURNAL OF IMMUNOTHERAPY (2020)
The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment
Ekaterina Kim et al.
LEUKEMIA (2020)
Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia
Christopher A. Eide et al.
LEUKEMIA (2020)
Regulation of B cell receptor-dependent NF-κB signaling by the tumor suppressor KLHL14
Jaewoo Choi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20
Xu-Wen Guan et al.
CELL DEATH & DISEASE (2020)
Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL
Andre F. Rendeiro et al.
NATURE COMMUNICATIONS (2020)
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas
Manit Munshi et al.
BLOOD CANCER JOURNAL (2020)
Cancer Stem Cells of Diffuse Large B Cell Lymphoma Are Not Enriched in the CD45+CD19- cells but in the ALDHhigh Cells
Shupeng Song et al.
JOURNAL OF CANCER (2020)
Ibrutinib-Induced Vasculitis in a Patient with Metastatic Colon Cancer Treated in Combination with Cetuximab
Jeffrey Chi et al.
CASE REPORTS IN ONCOLOGICAL MEDICINE (2020)
Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas
Yonghui Sun et al.
LEUKEMIA (2019)
The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma
Dong Hoon Lee et al.
MOLECULAR CARCINOGENESIS (2019)
Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL
Christian Schmidl et al.
NATURE CHEMICAL BIOLOGY (2019)
Mechanisms of resistance to CAR T cell therapy
Nirali N. Shah et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Emerging epigenetic-modulating therapies in lymphoma
David Sermer et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
A chemical approach for global protein knockdown from mice to non-human primates
Xiuyun Sun et al.
CELL DISCOVERY (2019)
Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma
C. Owen et al.
CURRENT ONCOLOGY (2019)
Ibrutinib and Venetoclax for First-Line Treatment of CLL
Nitin Jain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma
Liang Zhang et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Ibrutinib induces chromatin reorganisation of chronic lymphocytic leukaemia cells
Katie B. Holmes et al.
ONCOGENESIS (2019)
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
Constantine S. Tam et al.
BLOOD (2019)
A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant BtkC481S mutation in B-cell malignancies
Fu Gui et al.
BRITISH JOURNAL OF PHARMACOLOGY (2019)
Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study
P. Ghia et al.
HEMATOLOGICAL ONCOLOGY (2019)
Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma
Neeraj Jain et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
Yi-Xin Zou et al.
HEMATOLOGICAL ONCOLOGY (2019)
Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment
Ryan M. Young et al.
IMMUNOLOGICAL REVIEWS (2019)
Targeting PI3K and PLK1 to Overcome Ibrutinib-Venetoclax Resistance in Mantle Cell Lymphoma
Changying Jiang et al.
BLOOD (2019)
Targeting PRMT5 to Circumvent Acquired Ibrutinib Resistance in Mantle Cell Lymphoma
Shelby Sloan et al.
BLOOD (2019)
Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88L265P Mutant Diffuse Large B Cell Lymphoma
Sebastien L. Degorce et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Cardiovascular Toxicities Associated With Ibrutinib
Joe-Elie Salem et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia
Deborah M. Stephens et al.
BLOOD (2019)
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia
Jan A. Burger et al.
BLOOD (2019)
Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation
Rashmi Kanagal-Shamanna et al.
CANCER (2019)
Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial
Constantine S. Tam et al.
BLOOD (2019)
ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)
Jeff P. Sharman et al.
BLOOD (2019)
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
Carol Moreno et al.
LANCET ONCOLOGY (2019)
Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma
Rishu Agarwal et al.
NATURE MEDICINE (2019)
Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma
Hui Guo et al.
ONCOGENE (2019)
Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation, in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model
Yaya Chu et al.
ONCOIMMUNOLOGY (2019)
Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies
Isha Kapoor et al.
CELL DEATH & DISEASE (2019)
The Development and Applications of a Dual Optical Imaging System for Studying Glioma Stem Cells
Po-An Tai et al.
MOLECULAR IMAGING (2019)
Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia
Lindsey E. Roeker et al.
JAMA NETWORK OPEN (2019)
Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL
Mark B. Geyer et al.
JCI INSIGHT (2019)
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib
Farrukh T. Awan et al.
BLOOD ADVANCES (2019)
Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment
Martina Rudelius et al.
HAEMATOLOGICA (2018)
NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib
Christine Wolf et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway
K. Kondo et al.
LEUKEMIA (2018)
BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells
B. Sun et al.
LEUKEMIA (2018)
Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen
Michael Schaffer et al.
LEUKEMIA & LYMPHOMA (2018)
Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment
Yandong Shen et al.
LEUKEMIA & LYMPHOMA (2018)
Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment
Martina Rudelius et al.
HAEMATOLOGICA (2018)
Targeting glioblastoma-derived pericytes improves chemotherapeutic outcome
Daniel A. P. Guerra et al.
ANGIOGENESIS (2018)
Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation
Alexandru D. Buhimschi et al.
BIOCHEMISTRY (2018)
Development of the first small molecule histone deacetylase 6 (HDAC6) degraders
Ka Yang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects
Oshrat Hershkovitz-Rokah et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
Yonghui Sun et al.
CELL RESEARCH (2018)
Targeting the B cell receptor pathway in non-Hodgkin lymphoma
Kelly Valla et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI
Phillip L. R. Nicolson et al.
HAEMATOLOGICA (2018)
Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia
Christopher Pleyer et al.
LEUKEMIA & LYMPHOMA (2018)
Role of Bruton's tyrosine kinase in B cells and malignancies
Simar Pal Singh et al.
MOLECULAR CANCER (2018)
p110α Inhibition Overcomes Stromal Cell-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma
Jiyu Guan et al.
MOLECULAR CANCER THERAPEUTICS (2018)
A multiprotein supercomplex controlling oncogenic signalling in lymphoma
James D. Phelan et al.
NATURE (2018)
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
R. Schmitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
CD40L mediated alternative NFκB-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma
Hilka Rauert-Wunderlich et al.
CELL DEATH & DISEASE (2018)
Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?
Benjamin L. Lampson et al.
EXPERT REVIEW OF HEMATOLOGY (2018)
First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
John C. Byrd et al.
Oncotarget (2018)
Targeting of BMI-1 expression by the novel small molecule PTC596 in mantle cell lymphoma
Aya Maeda et al.
Oncotarget (2018)
Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI
Phillip L. R. Nicolson et al.
HAEMATOLOGICA (2018)
Reactive oxygen species mediate cancer stem-like cells and determine bortezomib sensitivity via Mcl-1 and Zeb-1 in mantle cell lymphoma
Sudjit Luanpitpong et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2018)
LOXO-305, A Next Generation Reversible BTK Inhibitor, for Overcoming Acquired Resistance to Irreversible BTK Inhibitors
Barbara Brandhuber et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth
Lorena Fontan et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies
Avirup Guha et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation
Sean D. Reiff et al.
CANCER DISCOVERY (2018)
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
J. A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia
Kamira Maharaj et al.
BLOOD ADVANCES (2018)
Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma
Jimmy Lee et al.
BLOOD ADVANCES (2018)
Comparison of Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL
Jordan Gauthier et al.
BLOOD (2018)
A Phase 1 Dose Escalation Study of ARQ 531 in Selected Patients with Relapsed or Refractory Hematologic Malignancies
Jennifer A. Woyach et al.
BLOOD (2018)
Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial
Nancy L. Bartlett et al.
BLOOD (2018)
Resistance to Ibrutinib in B Cell Malignancies: One Size Does Not Fit All
Bijal Shah et al.
TRENDS IN CANCER (2018)
XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of I kappa B
Mei Ming et al.
MOLECULAR CANCER THERAPEUTICS (2018)
A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader
Hai-Tsang Huang et al.
CELL CHEMICAL BIOLOGY (2018)
Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead
Daniel P. Bondeson et al.
CELL CHEMICAL BIOLOGY (2018)
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study
George M. Burslem et al.
CELL CHEMICAL BIOLOGY (2018)
B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma
Beiying Dai et al.
BLOOD (2017)
Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia
Nisar A. Amin et al.
CLINICAL CANCER RESEARCH (2017)
Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells
Noelia Purroy et al.
ONCOTARGET (2017)
Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants
Sun Ku Lee et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2017)
The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status
Anna Vidal-Crespo et al.
HAEMATOLOGICA (2017)
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials
Jennifer R. Brown et al.
HAEMATOLOGICA (2017)
Ibrutinib treatment improves T cell number and function in CLL patients
Meixiao Long et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib
Cameron J. Turtle et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
Jennifer A. Woyach et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile
Tjeerd Barf et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies
J. J. Shatzel et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2017)
Ibrutinib for patients with rituximab-refractory Waldenstrm's macro globulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2017)
PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment
D. Jones et al.
LEUKEMIA (2017)
Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia
J. Deng et al.
LEUKEMIA (2017)
EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL
Dorothy Brach et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Hsu-Ping Kuo et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition
T. K. Moyo et al.
ONCOGENE (2017)
Increased histone deacetylase 6 expression serves as a favorable prognostic factor for diffuse large B-cell lymphoma
Xiao-Ji Lin et al.
ONCOTARGETS AND THERAPY (2017)
Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma
Xiaohong Zhao et al.
NATURE COMMUNICATIONS (2017)
Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment
A. Paulus et al.
BLOOD CANCER JOURNAL (2017)
Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment
Ailin Guo et al.
ONCOTARGET (2017)
The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages
Lingyan Ping et al.
ONCOTARGET (2017)
The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status
Anna Vidal-Crespo et al.
HAEMATOLOGICA (2017)
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials
Jennifer R. Brown et al.
HAEMATOLOGICA (2017)
Mesenchymal stromal cells' role in tumor microenvironment: involvement of signaling pathways
Armel Herve Nwabo Kamdje et al.
CANCER BIOLOGY & MEDICINE (2017)
Microenvironment regulates the expression of miR-21 and tumor suppressor genes PTEN, PIAS3 and PDCD4 through ZAP-70 in chronic lymphocytic leukemia
Julia Carabia et al.
SCIENTIFIC REPORTS (2017)
MALT1 Inhibition Is Efficacious in Both Naive and Ibrutinib-Resistant Chronic Lymphocytic Leukemia
Nakhle S. Saba et al.
CANCER RESEARCH (2017)
A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers
Patrick F. Smith et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Targeting Glioma Stem Cell-Derived Pericytes Disrupts the Blood-Tumor Barrier and Improves Chemotherapeutic Efficacy
Wenchao Zhou et al.
CELL STEM CELL (2017)
B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
Leo Zhang et al.
CLINICAL CANCER RESEARCH (2017)
Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL
Kallesh D. Jayappa et al.
BLOOD ADVANCES (2017)
Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL
Sabah Kadri et al.
BLOOD ADVANCES (2017)
Acquired mutations associated with ibrutinib resistance in Waldenstrom macroglobulinemia
Lian Xu et al.
BLOOD (2017)
Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations
Patrizia Mondello et al.
JCI INSIGHT (2017)
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia
Inhye E. Ahn et al.
BLOOD (2017)
Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT
Juliane Paul et al.
CANCER CELL (2017)
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL
Ashton C. Lai et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy
Martin Skarzynski et al.
CLINICAL CANCER RESEARCH (2016)
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib - Findings from an Investigator-Initiated Phase II Study
Carsten U. Niemann et al.
CLINICAL CANCER RESEARCH (2016)
CD79B limits response of diffuse large B cell lymphoma to ibrutinib
Joo Hyun Kim et al.
LEUKEMIA & LYMPHOMA (2016)
Abstract C186: SNS-062 is a potent noncovalent BTK inhibitor with comparable activity against wild type BTK and BTK with an acquired resistance mutation
Minke E. Binnerts et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations
Adam R. Johnson et al.
ACS CHEMICAL BIOLOGY (2016)
Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment
Elisa ten Hacken et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2016)
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
Joseph A. Fraietta et al.
BLOOD (2016)
CD4OL-CD40 signaling on B-cell lymphoma response to BTK inhibitors
Zhijian Sun et al.
CANCER RESEARCH (2016)
The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma
Marco Ruella et al.
CLINICAL CANCER RESEARCH (2016)
The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein
Claudia Walliser et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Second-generation inhibitors of Bruton tyrosine kinase
Jingjing Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial
Michael L. Wang et al.
LANCET ONCOLOGY (2016)
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
Asher Chanan-Khan et al.
LANCET ONCOLOGY (2016)
Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes
F. Cervantes-Gomez et al.
LEUKEMIA (2016)
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Kanak Raina et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition
Jan A. Burger et al.
NATURE COMMUNICATIONS (2016)
Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes
Li Wei et al.
ONCOTARGET (2016)
Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL
Shruti Sharma et al.
ONCOTARGET (2016)
Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations
Chenglin Wu et al.
ONCOTARGET (2016)
Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia
Stefania Fiorcari et al.
ONCOTARGET (2016)
Sequence variants in patients with primary and acquired resistance to ibrutinib in the phase 3 MCL3001 (RAY) trial.
Georg Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
First-in-Human Phase 1a Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitor SNS-062 in Healthy Subjects
Linda L. Neuman et al.
BLOOD (2016)
Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation
Ta-Ming Liu et al.
BLOOD (2015)
Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib
Baohua Sun et al.
BLOOD (2015)
Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer
Leila Kokabee et al.
CANCER BIOLOGY & THERAPY (2015)
Bruton Tyrosine Kinase Is a Therapeutic Target in Stem-like Cells from Multiple Myeloma
Ye Yang et al.
CANCER RESEARCH (2015)
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Jing Lu et al.
CHEMISTRY & BIOLOGY (2015)
FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia
R. Angelo de Claro et al.
CLINICAL CANCER RESEARCH (2015)
Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages
Mercedes Borge et al.
HAEMATOLOGICA (2015)
Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy
Priscilla N. Kelly et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Targeting Wnt pathway in mantle cell lymphoma-initiating cells
Rohit Mathur et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia
Bing Xia et al.
LEUKEMIA RESEARCH (2015)
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wyndham H. Wilson et al.
NATURE MEDICINE (2015)
Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients
F. Boissard et al.
BLOOD CANCER JOURNAL (2015)
PRMT5 Is Required for Lymphomagenesis Triggered by Multiple Oncogenic Drivers
Yan Li et al.
CANCER DISCOVERY (2015)
Bruton’s tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer
Muhammad Ary Zucha et al.
Oncotarget (2015)
Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival
Valentina Trimarco et al.
ONCOTARGET (2015)
Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages
Mercedes Borge et al.
HAEMATOLOGICA (2015)
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
Kami J. Maddocks et al.
JAMA ONCOLOGY (2015)
Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling
Julie R. McMullen et al.
BLOOD (2014)
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity
Holbrook E. Kohrt et al.
BLOOD (2014)
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy
Jennifer A. Woyach et al.
BLOOD (2014)
Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma
M. Axelrod et al.
LEUKEMIA (2014)
Pharmacological and genomic profiling identifies NF-kappa B-targeted treatment strategies for mantle cell lymphoma
Rami Rahal et al.
NATURE MEDICINE (2014)
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ibrutinib Resistance in Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma
K. Teshima et al.
ONCOGENE (2014)
Cobblestone-Area Forming Cells Derived from Patients with Mantle Cell Lymphoma Are Enriched for CD133+ Tumor-Initiating Cells
Daniel J. Medina et al.
PLOS ONE (2014)
Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors
Michele Ceribelli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma
David Chiron et al.
CANCER DISCOVERY (2014)
Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib
Amin Aalipour et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2014)
Isolation of Side Population Cells in B-Cell Non-Hodgkin's Lymphomas
Mi Ran Lee et al.
ACTA HAEMATOLOGICA (2013)
ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia
Cassandra J. Vandenberg et al.
BLOOD (2013)
Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients
Betty Y. Chang et al.
BLOOD (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
B cell receptor signaling in chronic lymphocytic leukemia
Jan A. Burger et al.
TRENDS IN IMMUNOLOGY (2013)
Epigenetic Upregulation of IncRNAs at 13q14.3 in Leukemia Is Linked to the In Cis Downregulation of a Gene Cluster That Targets NF-kB
Angela Garding et al.
PLOS GENETICS (2013)
A Hypermorphic Missense Mutation in PLCG2, Encoding Phospholipase Cγ2, Causes a Dominantly Inherited Autoinflammatory Disease with Immunodeficiency
Qing Zhou et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2012)
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
Sabine Ponader et al.
BLOOD (2012)
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
Martin F. M. de Rooij et al.
BLOOD (2012)
A rare fraction of drug-resistant follicular lymphoma cancer stem cells interacts with follicular dendritic cells to maintain tumourigenic potential
Chung-Gi Lee et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling
Marcus Duehren-von Minden et al.
NATURE (2012)
The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia
Yair Herishanu et al.
BLOOD (2011)
Stem-like tumor cells confer drug resistant properties to mantle cell lymphoma
Hyun Joo Jung et al.
LEUKEMIA & LYMPHOMA (2011)
Oncogenically active MYD88 mutations in human lymphoma
Vu N. Ngo et al.
NATURE (2011)
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis et al.
NATURE (2010)
Prospective isolation of clonogenic mantle cell lymphoma-initiating cells
Zheng Chen et al.
STEM CELL RESEARCH (2010)
Spleen Tyrosine Kinase Is Overexpressed and Represents a Potential Therapeutic Target in Chronic Lymphocytic Leukemia
Maike Buchner et al.
CANCER RESEARCH (2009)
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma
Georg Lenz et al.
SCIENCE (2008)
分享论文
